RESOURCES & TOOLS 

Final_Vaccelerate.png

Explore EVI‘s

'Inventory and  

gap analysis report of

existing public outreach

material’, aiming to identify 

existing gaps in public 

knowledge on COVID-19

vaccine trials in Europe 

VACCELERATE

European Corona Vaccine Trial Accelerator

Context

EVI developed an ‘Inventory and gap analysis report of existing public outreach material’ as part of VACCELERATE, the pan-European platform for large-scale clinical vaccine trials. This will be an important infrastructure for all types of vaccine developers and implementers, ranging from public health authorities and research institutions to commercial vaccine developers.

In this contect, the inventory was created to identify and tackle existing gaps in public information material on COVID-19 vaccine trials in Europe, with special emphasis on identifying informational, promotional and educational material for underserved groups.

What is the Inventory? 

Highlights

1

COVID-19 Vaccine Trials-related online information was limited

2

Online outreach information did not significantly target underserved communities  

3

Bulk of media was mainly available in English, French and German

4

Higher number of media materials was not reflected in higher national vaccination rates

5

Vaccine Trials information did not depend on the number of clinical trials conducted

The inventory includes publicly available online information about COVID-19 vaccines, and specifically about clinical trials involving COVID-19 vaccines, (and other vaccine clinical trials) in Europe. It counts 2545 entries for different media such as websites, videos, audios, brochures, and flyers found available online from public, national and European official sources in 36 countries in Europe and neighbouring countries as well as multilateral organisations, including European and global NGOs. The information was categorised per topic, country (i.e., provenance of the institution that produced the material), language, type of media, and target audience. Material collection took place between May and July 2021.

01

This information is available for public use and consultation.

Findings summary   

- Coming soon -
- PDF file 3.4 Mb -
 - Excel file 1.5 Mb -

Contact details:

contact.us@euvaccine.eu
 

Acknowledgment: 

EU_flag.png

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101037867. This communication reflects the views only of the author, and the European Union cannot be held responsible for any use which may be made of the information contained therein. 

Vaccelerate-2021-04-20_7S_Turquoise_square.png